Gonadotrophine Chorionique Ibsa

Gonadotrophine Chorionique Ibsa is an injectable solution that contains recombinant human chorionic gonadotropin (hCG). It is supplied in a sterile vial for intramuscular or subcutaneous injection and is marketed in the European Union by prescription only. As a gonadotropin, it mimics luteinizing hormone activity to support reproductive processes in women and men under medical supervision. The product is stored refrigerated and should be used according to the prescribing information.

Gonadotrophine Chorionique Ibsa is employed in several reproductive‑endocrine indications where stimulation of luteinizing hormone receptors is required.

- Induction of ovulation in women with anovulatory or oligo‑ovulatory infertility. - Luteal phase support following assisted reproductive technology procedures such as in‑vitro fertilisation. - Stimulation of testosterone production in men with hypogonadotropic hypogonadism. - Management of cryptorchidism in pre‑pubertal boys to promote testicular descent. - Adjunct therapy in certain cases of delayed puberty where gonadotropin deficiency is identified.

Adverse reactions to Gonadotrophine Chorionique Ibsa are generally related to its hormonal activity and the injection site.

Common: - Injection‑site pain, erythema or swelling. - Mild headache. - Transient abdominal discomfort. - Nausea or mild gastrointestinal upset. - Temporary fatigue or dizziness.

Serious: - Ovarian hyperstimulation syndrome (OHSS) in women undergoing ovulation induction. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Allergic reactions including rash, urticaria, or anaphylaxis. - Testicular enlargement or pain in male patients. - Rapidly rising estrogen levels leading to estrogen‑dependent tumor growth (rare).

Before prescribing Gonadotrophine Chorionique Ibsa, clinicians should evaluate patient history and consider specific safety warnings.

- Assess for active or recent pregnancy; hCG can affect fetal development. - Review personal or family history of thromboembolic disease or clotting disorders. - Use caution in patients with uncontrolled hypertension or cardiovascular disease. - Monitor ovarian response closely to avoid severe ovarian hyperstimulation. - Evaluate for known hypersensitivity to hCG or any excipients in the formulation. - Adjust dose in patients with severe renal or hepatic impairment as advised. - Avoid use in individuals with active malignancies that are hormone‑sensitive.

Gonadotrophine Chorionique Ibsa may interact with other medications that influence coagulation, hormonal balance, or cardiovascular function.

Avoid: - Concurrent use of estrogen‑containing oral contraceptives or hormone therapy that may increase thrombotic risk. - Anticoagulant or antiplatelet agents that could exacerbate bleeding from ovarian cyst rupture. - GnRH agonists or antagonists that may alter the intended hormonal response.

Use with caution: - Testosterone replacement therapy in men, requiring monitoring of hormone levels. - Corticosteroids, which may mask signs of ovarian hyperstimulation. - Diuretics or antihypertensive drugs, as fluid shifts can affect blood pressure during treatment.